Jeremy Nighohossian is a senior fellow and economist at the Competitive Enterprise Institute, focusing on health care policy. His expertise is in healthcare antitrust and regulation including Certificate of Need regulations and competition and federal and state reimbursement policies. Jeremy writes on how government regulation and dominance of the healthcare sector stifle innovation, reduce quality, and raise costs.
Jeremy holds a Ph.D. in economics from Texas A&M University and a B.S. in Chemical Engineering from the University of Illinois. Before joining CEI, he worked at the Center for Healthcare Economics and Policy at FTI Consulting where he specialized in anti-trust and disputes in healthcare working on several projects with Compass Lexecon. While at FTI, Dr. Nighohossian built a policy analysis practice where he conducted analyses of state and national healthcare policies. Jeremy’s expertise has taken him around the world, testifying to the South Africa Competition Commission on hospital prices and how they relate to supply and he helped design a value-based payment system in the UK.
Authored by Jeremy Nighohossian
News
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…
FDA succeeds in approving new flu vaccine: CEI comment
The FDA has approved a flu vaccine made with mRNA technology, the same technology used for Moderna’s COVID-19 vaccine, the company announced on…
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring…
Blog
This week in health care policy: September 28 – October 2, 2026
Drug pricing CMS finalizes GLOBE pilot. On September 30, CMS finalized the Global Benchmark for Efficient Drug Pricing model, a…
This week in health care policy: September 21–25, 2026
Innovation watch FDA approves the first treatment for Sanfilippo syndrome. On September 17, the FDA approved Ultragenyx’s Fayuvi, a one-time…
How The No Surprises Act worsened the problem of surprise bills
Next week, Sen. Bill Cassidy (R-LA) will convene a roundtable to discuss adjustments to the 2020 No Surprises Act, which has come under…
Op-Eds/Articles
The Wall Street Journal
Don’t Expand Payroll Taxes for Social Security
In his column “Republicans’ Pre-Emptive Social Security Surrender” (Political Economics, Sept. 18), Joseph C. Sternberg makes a persuasive argument against expanding…
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
Issues & Insights
American Prosperity At 250
Americans are poised to celebrate 250 years of independence on July 4, but they seem to be pessimistic about the nation. When asked to…
Studies
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs,…
I, Pharmaceutical
The global pharmaceutical industry is complex. This is true not only in the number of countries involved but the range of products, the sets…
Citations
The Epoch Times
Feds Aim to Tighten Drug Payment Loophole, Save Taxpayers Billions
CEI expert Jeremy Nighohossian was cited by the Epoch Times in their explanation of rule 340b in hospitals. Large hospitals are able to…
PCMA
No More Excuses After Pharma-Backed PBM Reform Becomes Law
PCMA cited CEI’s expert on prescription prices Going further, a renewed focus on the way Big Pharma games the patent system to…
Freedom Works Radio
Jeremy Nighohossian, Competitive Enterprise Institute “Trump Healthcare Plan a Mixed Bag”: Freedom Works Radio Show
Freedom Works Radio show interviews CEI’s expert on healthcare Listen to Freedom Works Radio…
Regulatory Comments
CEI Comments on 340B Payment Change
The Competitive Enterprise Institute (CEI) submits these comments in support of several of the provisions in the rule recently proposed by CMS. Founded in…
CEI Comments on Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program
Comments of the Competitive Enterprise Institute Dear Dr. Oz, The Competitive Enterprise Institute (CEI) submits these comments in support of several provisions…
CEI Comments on Global Benchmark for Efficient Drug Pricing (GLOBE) Model
Comments of the Competitive Enterprise Institute Dear Dr. Oz, The Competitive Enterprise Institute (CEI) submits these comments in opposition to the creation…
Podcast Episodes
Obamacare Problems with Jeremy Nighohossian
This week we talk about the unintended consequences of the Sarbanes-Oxley Act of 2002, decarbonization of economic growth, and resources for reporting government corruption at...